Skip to content
2000
Volume 25, Issue 13
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Buzhong Yiqi decoction (BZYQ) is a classical traditional Chinese formula that has shown potential in alleviating diabetic nephropathy (DN). However, its underlying mechanisms remain unclear.

Objective

We aimed to explore the potential targets and mechanisms of action of BZYQ in DN.

Materials and Methods

A DN rat model was induced using a high-fat and high-sugar diet combined with intraperitoneal injection of streptozotocin (STZ), followed by treatment with different doses of BZYQ. Initially, the protective effects of BZYQ on renal tissue were assessed by measuring fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), 24-hour urinary total protein (24h-UTP), urinary albumin (ALB), and serum creatinine (SCr) after administration, along with performing hematoxylin-eosin (HE) staining. Subsequently, transcriptomics and bioinformatics approaches were employed to identify the action targets and potential mechanisms of BZYQ in DN rats. Finally, real-time PCR and Western blot analyses were conducted to validate key targets and mechanisms.

Results

We observed significant improvements in renal injury in DN rats treated with medium and high doses of BZYQ. Transcriptomic and bioinformatic analyses identified NLRP3, ASC, caspase-1, GSDMD, IL-1β, and IL-18 as hub genes, along with differential expression of immune-related transcription factors T-bet and GATA-3 in various transcriptomes. In the validation phase, the mRNA and protein expressions of NLRP3, ASC, caspase-1, GSDMD, IL-18, IL-1β, and T-bet were significantly elevated in the DN rat model group, while GATA-3 mRNA and protein levels were significantly decreased; BZYQ was able to reverse these changes.

Conclusion

BZYQ has been found to have a protective effect on renal tissue damage in DN rats, potentially related to the inhibition of NLRP3 inflammasome pathway activation and the improvement of Th1/Th2 immune cell balance.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303379062250327184950
2025-04-21
2025-12-09

  • From This Site

    /content/journals/emiddt/10.2174/0118715303379062250327184950
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/13/EMIDDT-25-13-07.html?itemId=/content/journals/emiddt/10.2174/0118715303379062250327184950&mimeType=html&fmt=ahah

References

  1. SelbyN.M. TaalM.W. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines.Diabetes Obes. Metab.202022S1Suppl. 131510.1111/dom.1400732267079
     [Google Scholar]
  2. CherneyD.Z. TuttleK.R. Liraglutide for the treatment of type 2 diabetes and safety in diabetic kidney disease.Clin. J. Am. Soc. Nephrol.202015444444610.2215/CJN.0126012032149722
     [Google Scholar]
  3. ReutensA.T. AtkinsR.C. Epidemiology of diabetic nephropathy.Contrib. Nephrol.20111701710.1159/00032493421659752
     [Google Scholar]
  4. LinZ. HuoH. HuangM. TaoJ. YangY. GuoJ. Fufang Zhenzhu Tiaozhi (FTZ) capsule ameliorates diabetic kidney disease in mice via inhibiting the SGLT2/glycolysis pathway.J. Ethnopharmacol.202433511869810.1016/j.jep.2024.11869839151712
     [Google Scholar]
  5. FanJ. Decoction with modifications for the treatment of 100 cases of diabetic nephropathy.Shanxi Trad. Chin. Med.2011328960962
     [Google Scholar]
  6. GuoY. SuX. YangC. ZhuJ. LiY. SongY. Research progress on the treatment of kidney diseases with buzhong yiqi decoction.J. Liaoning TCM20174461328133110.13192/j.issn.1000‑1719.2017.06.074
     [Google Scholar]
  7. DaiX. LiS. Clinical observation of 60 cases of diabetic nephropathy treated with modified Buzhong Yiqi Decoction.J. Prim. Med. Forum.201721324544454610.19435/j.1672‑1721.2017.32.083
     [Google Scholar]
  8. KangY.J. Herbogenomics: From traditional Chinese medicine to novel therapeutics.Exp. Biol. Med.200823391059106510.3181/0802‑MR‑4718535158
     [Google Scholar]
  9. LiuC. YinZ. FengT. ZhangM. ZhouZ. ZhouY. An integrated network pharmacology and RNA-Seq approach for exploring the preventive effect of Lonicerae japonicae flos on LPS-induced acute lung injury.J. Ethnopharmacol.202126411336410.1016/j.jep.2020.11336432916233
     [Google Scholar]
  10. JiaC. WuH. YangA. ChenA. WangX. DingS. FanB. ZhouG. LiZ. ChenJ. Mechanism research of QingReJieDu formula for treating hepatitis b virus based on network pharmacology.Phytomedicine202413515591510.1016/j.phymed.2024.15591539550917
     [Google Scholar]
  11. LiuD. WeiC. GuanL. JuW. XiangS. LianF. Combining single-cell RNA sequencing and network pharmacology to explore the target of cangfu daotan decoction in the treatment of obese polycystic ovary syndrome from an immune perspective.Front. Pharmacol.202415145130010.3389/fphar.2024.145130039539629
     [Google Scholar]
  12. Shivam KumarS. GuptaA.K. Review on in-vitro techniques and in-vivo animals models for screening diabetes and diabetic complications.Curr. Diabetes Rev.2024201e13042321573410.2174/157339981966623041308534137069711
     [Google Scholar]
  13. ZhangX. ZhangJ. ZhouZ. XiongP. ChengL. MaJ. WenY. ShenT. HeX. WangL. ZhangY. XiaoC. Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease.J. Ethnopharmacol.202432511782810.1016/j.jep.2024.11782838325669
     [Google Scholar]
  14. ZhangW. WangY. YuH. JinZ. YuanY. LiuL. ZhouJ. Exploring the mechanism of Erteng-Sanjie capsule in treating gastric and colorectal cancers via network pharmacology and in-vivo validation.J. Ethnopharmacol.202432711794510.1016/j.jep.2024.11794538428659
     [Google Scholar]
  15. BonnerR. AlbajramiO. HudspethJ. UpadhyayA. Diabetic kidney disease.Prim. Care202047464565910.1016/j.pop.2020.08.00433121634
     [Google Scholar]
  16. MłynarskaE. BuławskaD. CzarnikW. HajdysJ. MajchrowiczG. PrusinowskiF. StabrawaM. RyszJ. FranczykB. Novel insights into diabetic kidney disease.Int. J. Mol. Sci.202425181022210.3390/ijms25181022239337706
     [Google Scholar]
  17. EfiongE.E. BazirehH. FuchsM. AmadiP.U. EffaE. SharmaS. SchmadererC. Crosstalk of hyperglycaemia and cellular mechanisms in the pathogenesis of diabetic kidney disease.Int. J. Mol. Sci.202425201088210.3390/ijms25201088239456664
     [Google Scholar]
  18. WangM. YaoF. ChenN. WuT. YanJ. DuL. ZengS. DuC. The advance of single cell transcriptome to study kidney immune cells in diabetic kidney disease.BMC Nephrol.202425141210.1186/s12882‑024‑03853‑y39550562
     [Google Scholar]
  19. ZhangJ. ZhangR. WangY. WuY. LiH. HanQ. GuoR. WangT. WangJ. GrungP. LiuF. Effects of neutrophil–lymphocyte ratio on renal function and histologic lesions in patients with diabetic nephropathy.Nephrology201924111115112110.1111/nep.1351730346090
     [Google Scholar]
  20. YangX. SongN. WangZ. ZhouX. XuJ. CaoH. ChenW GaoT. Buzhong Yiqi decoction improves immune dysregulation in autoimmune thyroiditis mice by regulating Th17 cells via miR-155 intervention.Chin. Arch. TCM2019371364010.13193/j.issn.1673‑7717.2019.01.008
     [Google Scholar]
  21. LiX. ZhaoZ. ChenY. CaoH. ChenS. WangZ. GaoT. LiuZ. YangX. Mechanism of Buzhong Yiqi Decoction in improving autoimmune thyroiditis through miR-155/Ndfip1/Pten axis regulation of Th17 cells.Chin J Exp Tradit Med Form20243018192610.13422/j.cnki.syfjx.20241039
     [Google Scholar]
  22. QiY. HanX. WangQ. YangQ. WangY. Mechanism of Buzhong Yiqi Decoction in treating allergic rhinitis based on network pharmacology analysis.World Chin. Med.2021162029872991
     [Google Scholar]
  23. WuY. GuoZ. DengW. QiX. XuJ. LuY. LiangB. Clinical efficacy and effects of Buzhong Yiqi Decoction on bone turnover markers after surgery for osteoporotic vertebral compression fractures based on the theory of “Spleen governing muscles.Chin. J. Exp. Tradit. Med. Formulae.20222817919710.13422/j.cnki.syfjx.20221323
     [Google Scholar]
  24. ZhangQ. BaiY. WangW. LiJ. ZhangL. TangY. YueS. Role of herbal medicine and gut microbiota in the prevention and treatment of obesity.J. Ethnopharmacol.202330511612710.1016/j.jep.2022.11612736603782
     [Google Scholar]
  25. ZhaoW. HeC. JiangJ. ZhaoZ. YuanH. WangF. ShenB. The role of discoid domain receptor 1 on renal tubular epithelial pyroptosis in diabetic nephropathy.Korean J. Physiol. Pharmacol.202226642743810.4196/kjpp.2022.26.6.42736302618
     [Google Scholar]
  26. Machado JúniorP.A.B. LassA. PilgerB.I. FornazariR. MoraesT.P. PinhoR.A. SGLT2 inhibitors and NLRP3 inflammasome: Potential target in diabetic kidney disease.J. Bras. Nefrol.2024464e2023018710.1590/2175‑8239‑jbn‑2023‑0187en39412512
     [Google Scholar]
  27. ZhuW. LiY.-Y. ZengH.-X. LiuX.-Q. SunY.-T. JiangL. XiaL.-L. WuY.-G. Carnosine alleviates podocyte injury in diabetic nephropathy by targeting caspase-1-mediated pyroptosis.Int. Immunopharmacol.2021101Pt B10823610.1016/j.intimp.2021.108236
     [Google Scholar]
  28. YuanS. WangY. LiZ. ChenX. SongP. ChenA. QuZ. WenS. LiuH. ZhuX. GasderminD. Gasdermin D is involved in switching from apoptosis to pyroptosis in TLR4-mediated renal tubular epithelial cells injury in diabetic kidney disease.Arch. Biochem. Biophys.202272710934710.1016/j.abb.2022.10934735809639
     [Google Scholar]
  29. GuoH. PanC. ChangB. WuX. GuoJ. ZhouY. LiuH. ZhuZ. ChangB. ChenL. Triptolide improves diabetic nephropathy by regulating Th cell balance and macrophage infiltration in rat models of diabetic nephropathy.Exp. Clin. Endocrinol. Diabetes2016124638939810.1055/s‑0042‑10608327328403
     [Google Scholar]
  30. ChengY. ZhangJ. HouW. WangD. LiF. ZhangY. YuanF. Immunoregulatory effects of sinomenine on the T-bet/GATA-3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritis.Int. Immunopharmacol.200997-889489910.1016/j.intimp.2009.03.01419336263
     [Google Scholar]
  31. PeineM. RauschS. HelmstetterC. FröhlichA. HegazyA.N. KühlA.A. GreveldingC.G. HöferT. HartmannS. LöhningM. Stable T-bet(+)GATA-3(+) Th1/Th2 hybrid cells arise in vivo, can develop directly from naive precursors, and limit immunopathologic inflammation.PLoS Biol.2013118e100163310.1371/journal.pbio.100163323976880
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303379062250327184950
Loading
Comprehensive Transcriptomic and Bioinformatic Analysis of the Mechanism of Buzhong Yiqi Decoction in the Improvement of Diabetic Nephropathy
Endocr Metab Immune Disord Drug Targets 25, 1099 (2025); https://doi.org/10.2174/0118715303379062250327184950
/content/journals/emiddt/10.2174/0118715303379062250327184950
/content/journals/emiddt/10.2174/0118715303379062250327184950
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): bioinformatic analysis; buzhong Yiqi decoction; Diabetic nephropathy; DN rat model; Th1/Th2 immune cell; transcriptomics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test